Navigation Links
Griffin Securities Analyst Interviews Unilife Corp. CEO in a Two-Part Video Series

NEW YORK, Oct. 25, 2012 /PRNewswire/ -- Griffin Securities announced today that Dr. Keith Markey, the Scientific Director of Griffin's research division, recently interviewed Alan Shortall, CEO of Unilife Corporation ("Unilife") (NASDAQ: UNIS; ASX: UNS) about the company's continued progress in the commercialization of its portfolio of proprietary injectable drug delivery systems as well as a Q&A covering many investor questions that have arose over the past few weeks. 

The video interview series will be made available in two parts:

  • Part One – Update on the Unilife Business and Financial Discussion
  • Part Two – Unilife's Device Platforms and New Commercial Opportunities

Part One of the video interview and the associated transcript is now available on the Unilife website at The video is also available on YouTube at

Part Two of the video interview and associated transcript will be made available to the public at 9.30 a.m. U.S. Eastern Time, Friday, October 26, 2012. Links to this Part Two of the interview will be provided at this time.

"I believe this two part video series offers an in-depth overview of the questions that Unilife investors have been asking recently as it pertains to the business and the company's stock.  Alan opens up about why investing in R&D is so important for Unilife as a business and the short-term impacts as well as the long-term opportunities for Unilife as it pertains to the company's relationships with its pharmaceutical company customers," stated Dr. Markey.

For Griffin Securities' reports on Unilife Corporation, including full disclosure statements, please contact Dr. Keith Markey at 212-514-7914 or via email,

About Unilife Corporation

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife collaborates with pharmaceutical and biotechnology companies seeking innovative, differentiated devices that can enable or enhance the delivery of injectable drugs and vaccines supplied in either a liquid stable or lyophilized form. The Unifill syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of this diversified portfolio. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, bolus injectors, infusion pumps and targeted delivery systems. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit     

About Griffin Securities, Inc. ("Griffin Securities")

Griffin Securities, a FINRA (formerly known as the NASD) member firm with its principal office in New York, New York, USA is an investment banking firm providing corporate finance, merger and acquisitions, brokerage, and investment opportunities for institutional, corporate, and private clients. The analyst(s) are employed by Griffin Securities. Our research professionals provide important input into our investment banking and other business selection processes. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

Griffin Securities may from time to time perform corporate finance or other services for some companies described herein and may occasionally possess material, nonpublic information regarding such companies. This information is not used in preparation of the opinions and estimates herein. While the information contained in this report and the opinions contained herein are based on sources believed to be reliable, Griffin Securities has not independently verified the facts, assumptions and estimates contained in this report. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this report.

The information contained herein is not a complete analysis of every material fact in respect to any company, industry or security. This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of clients of Griffin Securities. It does not take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. Certain transactions - including those involving futures, options, and other derivatives as well as non-investment-grade securities - give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. The information contained in this report is subject to change without notice and Griffin Securities assumes no responsibility to update the report. In addition, regulatory, compliance, or other reasons may prevent us from providing updates.

General: UNIS-G

Scientific Director
Griffin Securities
Phone: 212-514-7914

SOURCE Unilife Corporation; Griffin Securities, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Guggenheim Securities Expands Healthcare Equity Research Team
2. Securities Lawyers at Goldfarb LLP Seeking More Money, Information for Stockholders of Par Pharmaceutical Companies, Inc.
3. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
4. Insmed To Present At JMP Securities 7th Annual Healthcare Conference
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Delcath To Present At JMP Securities Healthcare Conference On July 12
7. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
8. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
9. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
10. Solta Medical to Present at the JMP Securities Healthcare Conference
11. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
Post Your Comments:
(Date:10/12/2015)... -- Given the intricacy of the anatomy and ... an ophthalmic drug effectively to a specific ocular site. Several ... delivery. These include dilution of a drug by tears, clearance ... drug permeation issues with respect to the cornea, sclera and ... is lost due to the aforementioned barriers. --> ...
(Date:10/12/2015)... WASHINGTON , Oct. 12, 2015  Former White House ... Press Secretary for the House Narcotics Committee, Robert Weiner ... "Rewriting Drug Policy." The two emphasize that this is now ... Clinton to Jeb Bush , Carly Fiorina ... Sordello cite the newest federal statistics, which they call "a ...
(Date:10/12/2015)... Corporation (NASDAQ: LMNX ) today announced that it expects ... 2015 on Monday, November 2, 2015. A press release announcing ... trading. --> --> ... highlights and financial results for the third quarter ended September ... time. . Simply log on to ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... communities, and the Florida Apartment Association (FAA) has partnered with the Florida Department ... meet the demand. , The FAA Smoke-Free Multifamily Housing Program launched last ...
(Date:10/13/2015)... ... , ... Just under three months ago, eMarketing Concepts forever changed ... effectively offering all of their services for just a buck in the first month. ... phone calls from interested buyers. As a genuine one-stop-shop for internet marketing, EMC has ...
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... ... announced the release of a new PDF automation tool to batch conversions ... and business mandates with 100% document fidelity. , CADConverter eliminates the complexity requirement ...
(Date:10/13/2015)... ... October 13, 2015 , ... The Bill Howe Family of Companies ... offering expert reconstruction and flood remediation services. Family-owned and operated for 35 years, they ... the Best San Diego plumber two years in a row from the Union Tribune ...
(Date:10/13/2015)... Somerset, N.J. (PRWEB) , ... October 13, 2015 ... ... advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal ... Science and Technology, and will lead a new, dedicated global team of drug ...
Breaking Medicine News(10 mins):